| Not Yet Recruiting | Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced M NCT07514793 | Fudan University | Phase 2 |
| Withdrawn | Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma NCT06654050 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Pr NCT07420010 | Weijia Fang, MD | EARLY_Phase 1 |
| Recruiting | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors NCT07277413 | IDEAYA Biosciences | Phase 1 |
| Recruiting | Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma NCT07126509 | University of Chicago | N/A |
| Recruiting | 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection NCT06503146 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma NCT07131345 | National Cancer Center, China | Phase 1 / Phase 2 |
| Enrolling By Invitation | A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Product NCT06885424 | A2 Biotherapeutics Inc. | — |
| Recruiting | Prospective Data Collection Initiative on Thoracic Malignancies NCT06996249 | Dutch Society of Physicians for Pulmonology and Tuberculosis | — |
| Recruiting | Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumo NCT06885697 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Lead-212 PSV359 Therapy for Patients With Solid Tumors NCT06710756 | Perspective Therapeutics | Phase 1 / Phase 2 |
| Recruiting | An International Study on Pediatric Patients With Rare Tumors. NCT07072143 | Azienda Ospedaliera di Padova | — |
| Not Yet Recruiting | Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors NCT06652529 | Aromics Therapeutics | Phase 1 |
| Withdrawn | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs NCT04985357 | Travera Inc | — |
| Recruiting | A Study of VET3-TGI in Patients With Solid Tumors NCT06444815 | KaliVir Immunotherapeutics | Phase 1 |
| Active Not Recruiting | A Study of SGN-MesoC2 in Advanced Solid Tumors NCT06466187 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | New Preclinical and Clinical Approaches to Mesothelioma NCT06536179 | Marco Emilio Bianchi | — |
| Recruiting | Agnostic Therapy in Rare Solid Tumors NCT06638931 | Instituto do Cancer do Estado de São Paulo | Phase 2 |
| Recruiting | Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma NCT05932199 | Baylor College of Medicine | Phase 1 / Phase 2 |
| Recruiting | A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors NCT06452160 | BridGene Biosciences Inc. | Phase 1 |
| Recruiting | A Study of Sacituzumab Govitecan in People With Mesothelioma NCT06477419 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | GPC3/Mesothelin-CAR-γδT Cells Against Cancers NCT06196294 | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 |
| Not Yet Recruiting | Studying the Clinical Trial Experiences of Patients With Mesothelioma NCT05819580 | Power Life Sciences Inc. | — |
| Recruiting | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With So NCT06051695 | A2 Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Suspended | Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition NCT05960773 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | EXTRA-Meso (EXercise TheRApy in Mesothelioma) Feasibility NCT06491784 | NHS Greater Glasgow and Clyde | N/A |
| Recruiting | Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU NCT06538376 | Brigham and Women's Hospital | N/A |
| Recruiting | Immune Microenvironment and Gene Expression Profiling in Mesothelioma NCT06581549 | Istituto Oncologico Veneto IRCCS | — |
| Terminated | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Can NCT06034860 | Molecular Templates, Inc. | Phase 1 |
| Recruiting | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers NCT05873686 | Nuvectis Pharma, Inc. | Phase 1 |
| Recruiting | A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma NCT06057935 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Withdrawn | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss NCT06090318 | Rain Oncology Inc | Phase 1 / Phase 2 |
| Recruiting | MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI NCT05730816 | Brigham and Women's Hospital | Phase 2 |
| Unknown | Folinic Acid for Prevention of Pemetrexed-induced Toxicity NCT06010277 | Amphia Hospital | Phase 4 |
| Active Not Recruiting | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors NCT05571839 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366 | Genmab | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advance NCT05544929 | Novartis Pharmaceuticals | Phase 1 |
| Unknown | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas NCT05415098 | Ascentage Pharma Group Inc. | Phase 1 |
| Completed | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) NCT05461430 | Travera Inc | — |
| Active Not Recruiting | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer NCT05451849 | TCR2 Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion NCT05245500 | Bristol-Myers Squibb | Phase 1 |
| Unknown | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors NCT05311618 | NGM Biopharmaceuticals, Inc | Phase 1 |
| Terminated | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tu NCT05070247 | Takeda | Phase 1 / Phase 2 |
| Unknown | Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including NCT05278975 | RS Oncology LLC | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced o NCT05215574 | NGM Biopharmaceuticals, Inc | Phase 1 |
| Active Not Recruiting | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced So NCT05238883 | HiFiBiO Therapeutics | Phase 1 |
| Recruiting | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies NCT05627960 | A&G Pharmaceutical Inc. | Phase 1 |
| Withdrawn | Cryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma NCT04429204 | Jonsson Comprehensive Cancer Center | N/A |
| Completed | A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothel NCT05041062 | University of Chicago | Phase 2 |
| Recruiting | Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing NCT04981119 | A2 Biotherapeutics Inc. | — |
| Active Not Recruiting | A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors NCT04857372 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Intravenous Magnesium in Patients Receiving Cisplatin NCT04481672 | Dana-Farber Cancer Institute | Phase 1 |
| Terminated | Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma NCT04840615 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Mal NCT04913337 | NGM Biopharmaceuticals, Inc | Phase 1 / Phase 2 |
| Completed | The Registry of Oncology Outcomes Associated With Testing and Treatment NCT04028479 | Taproot Health | — |
| Active Not Recruiting | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Express NCT04802876 | SOLTI Breast Cancer Research Group | Phase 2 |
| Recruiting | Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biops NCT04431024 | National Cancer Institute (NCI) | — |
| Terminated | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid NCT04272034 | Incyte Corporation | Phase 1 |
| Recruiting | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors NCT04665206 | Vivace Therapeutics, Inc | Phase 1 / Phase 2 |
| Recruiting | Olaparib in Patients With HRD Malignant Mesothelioma NCT04515836 | University of Chicago | Phase 2 |
| Completed | DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma NCT04334759 | PrECOG, LLC. | Phase 3 |
| Unknown | UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC NCT04940637 | University of Turin, Italy | Phase 2 |
| Unknown | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity NCT04631731 | Western Sydney Local Health District | Phase 1 / Phase 2 |
| Terminated | Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders NCT02748798 | Thunder Bay Regional Health Research Institute | EARLY_Phase 1 |
| Completed | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid NCT04242199 | Incyte Corporation | Phase 1 |
| Active Not Recruiting | The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance NCT04450043 | Massachusetts General Hospital | N/A |
| Terminated | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors NCT04301011 | Turnstone Biologics, Corp. | Phase 1 |
| Unknown | αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors NCT04489862 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | EARLY_Phase 1 |
| Active Not Recruiting | Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma NCT04300244 | Åslaug Helland | Phase 2 |
| Completed | Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels NCT04537715 | Epizyme, Inc. | Phase 1 |
| Completed | 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours NCT04375267 | Vastra Gotaland Region | Phase 1 |
| Withdrawn | A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma NCT04214015 | ProgenaBiome | — |
| Completed | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors NCT03023319 | Nagla Abdel Karim | Phase 1 |
| Completed | A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelio NCT04153565 | Merck Sharp & Dohme LLC | Phase 1 |
| Recruiting | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers NCT03935893 | Udai Kammula | Phase 2 |
| Recruiting | Stereotactic Magnetic Resonance Guided Radiation Therapy NCT04115254 | Dana-Farber Cancer Institute | N/A |
| Completed | Phase I Trial HIPEC With Nal-irinotecan NCT04088786 | Stony Brook University | Phase 1 |
| Active Not Recruiting | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid T NCT03983954 | NeoTX Therapeutics Ltd. | Phase 1 |
| Active Not Recruiting | Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma NCT03918252 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Terminated | Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With NCT02859415 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | First-in-human Study of S-588210 (S-488210+S-488211) NCT04316689 | Shionogi | Phase 1 |
| Completed | Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma NCT04040231 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Suspended | A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease NCT04031469 | ProgenaBiome | — |
| Terminated | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumor NCT04234113 | SOTIO Biotech AG | Phase 1 |
| Completed | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors NCT03881488 | Compass Therapeutics | Phase 1 |
| Active Not Recruiting | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer NCT03907852 | TCR2 Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Othe NCT03830229 | National Cancer Institute (NCI) | — |
| Terminated | Dose Individualization of Pemetrexed - IMPROVE-II NCT03655821 | Radboud University Medical Center | Phase 4 |
| Completed | Dose Individualization of Pemetrexed - IMPROVE-III NCT03655834 | Radboud University Medical Center | Phase 4 |
| Completed | Dose Individualization of Pemetrexed - IMPROVE-I NCT03656549 | Radboud University Medical Center | Phase 4 |
| Terminated | Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma NCT03644550 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarker NCT03683680 | Dana-Farber Cancer Institute | N/A |
| Completed | Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma NCT03867578 | University of Chicago | N/A |
| Terminated | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors NCT03685591 | Pfizer | Phase 1 |
| Completed | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies NCT03652077 | Incyte Corporation | Phase 1 |
| Completed | A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma NCT04056026 | ProgenaBiome | EARLY_Phase 1 |
| Completed | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) NCT03207347 | University of Florida | Phase 2 |
| Completed | Olaparib in People With Malignant Mesothelioma NCT03531840 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors NCT03517488 | Xencor, Inc. | Phase 1 |
| Completed | DENdritic Cell Immunotherapy for Mesothelioma NCT03610360 | Amphera BV | Phase 2 / Phase 3 |
| Completed | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies NCT03538028 | Incyte Biosciences International Sàrl | Phase 1 |
| Recruiting | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or NCT03556228 | VM Oncology, LLC | Phase 1 / Phase 2 |
| Unknown | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies NCT03638206 | Shenzhen BinDeBio Ltd. | Phase 1 / Phase 2 |
| Terminated | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peri NCT03436732 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Cardiac MRI Biomarker Testing (GCC 1618) NCT02688166 | University of Maryland, Baltimore | — |
| Terminated | Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma NCT03319537 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin NCT02709512 | Polaris Group | Phase 2 / Phase 3 |
| Unknown | Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) NCT02758587 | NHS Greater Glasgow and Clyde | Phase 1 / Phase 2 |
| Completed | Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma NCT02899195 | PrECOG, LLC. | Phase 2 |
| Terminated | A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma NCT03075527 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma NCT03063450 | University of Southampton | Phase 3 |
| Withdrawn | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumo NCT02661100 | Case Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Completed | A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirum NCT03560973 | Gruppo Oncologico Italiano di Ricerca Clinica | Phase 2 |
| Suspended | Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment NCT01627795 | Oshadi Drug Administration | Phase 1 / Phase 2 |
| Completed | Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Thera NCT02899299 | Bristol-Myers Squibb | Phase 3 |
| Completed | Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma NCT02784171 | Canadian Cancer Trials Group | Phase 2 / Phase 3 |
| Completed | Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on NCT02948413 | National Institutes of Health Clinical Center (CC) | — |
| Completed | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients NCT02903914 | Incyte Corporation | Phase 1 |
| Terminated | Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for NCT02838745 | Baylor College of Medicine | Phase 1 |
| Completed | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated NCT02875548 | Epizyme, Inc. | Phase 1 / Phase 2 |
| Completed | Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma NCT02798536 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma NCT02860286 | Epizyme, Inc. | Phase 2 |
| Terminated | Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma NCT02613299 | Mayo Clinic | — |
| Completed | MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma NCT02592551 | Baylor College of Medicine | Phase 2 |
| Completed | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors NCT02611024 | PharmaMar | Phase 1 / Phase 2 |
| Completed | Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Pati NCT02716272 | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 |
| Terminated | Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for NCT02613312 | Mayo Clinic | — |
| Completed | Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma NCT02611037 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Vinorelbine in Mesothelioma NCT02139904 | Wales Cancer Trials Unit | Phase 2 |
| Terminated | Staging Procedures to Diagnose Malignant Pleural Mesothelioma NCT02648763 | Mayo Clinic | — |
| Active Not Recruiting | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) NCT02628067 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) NCT02610140 | Bayer | Phase 2 |
| Withdrawn | Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication NCT02511600 | M.D. Anderson Cancer Center | Phase 3 |
| Terminated | Safety Study of MGD009 in B7-H3-expressing Tumors NCT02628535 | MacroGenics | Phase 1 |
| Terminated | Intrapleural Cryotherapy for Malignant Pleural Mesothelioma NCT02464904 | Mayo Clinic | N/A |
| Completed | Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma NCT02293005 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Mesothelioma and Radical Surgery 2 NCT02040272 | Royal Brompton & Harefield NHS Foundation Trust | N/A |
| Active Not Recruiting | Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Sur NCT02414269 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome NCT04792463 | Mohamed Abdel-Rahman | — |
| Unknown | Dendritic Cells Loaded With Allogeneous Cell Lysate in Mesothelioma Patients NCT02395679 | Erasmus Medical Center | Phase 1 |
| Terminated | Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma NCT02385812 | University of Calgary | Phase 2 |
| Terminated | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy NCT02062632 | Mayo Clinic | Phase 2 |
| Completed | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors NCT02071862 | Calithera Biosciences, Inc | Phase 1 |
| Recruiting | Rapid Autopsy and Procurement of Cancer Tissue NCT01851395 | National Cancer Institute (NCI) | — |
| Recruiting | Integrated Cancer Repository for Cancer Research NCT02012699 | University of Nebraska | — |
| Completed | Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion NCT01997190 | Candel Therapeutics, Inc. | Phase 1 |
| Terminated | Nintedanib (BIBF 1120) in Mesothelioma NCT01907100 | Boehringer Ingelheim | Phase 2 / Phase 3 |
| Recruiting | Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma NCT01950572 | National Cancer Institute (NCI) | — |
| Unknown | Thromboelastography During Surgery for Malignant Pleural Mesothelioma NCT01912547 | Brigham and Women's Hospital | — |
| Completed | Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study. NCT02078700 | Azienda USL Reggio Emilia - IRCCS | Phase 2 |
| Unknown | A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma NCT01569919 | Wales Cancer Trials Unit | Phase 2 |
| Unknown | Early Detection of Lung Cancer and Mesothelioma in Workers Exposed to Asbestos NCT01719068 | British Columbia Cancer Agency | — |
| Terminated | Mithramycin for Lung, Esophagus, and Other Chest Cancers NCT01624090 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma NCT01604005 | Brynn Chappell | Phase 3 |
| Terminated | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer NCT01583686 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothe NCT01776385 | Centre Hospitalier Universitaire de Nice | N/A |
| Completed | A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers NCT01521325 | Morphotek | Phase 1 |
| Enrolling By Invitation | Molecular Analysis of Thoracic Malignancies NCT01385722 | Stanford University | — |
| Terminated | Amatuximab for High Mesothelin Cancers NCT01413451 | National Cancer Institute (NCI) | EARLY_Phase 1 |
| Completed | Chest Wall Motion Analysis in Disease NCT02958683 | Heart of England NHS Trust | — |
| Completed | Do Your Genes Put You at a Higher Risk of Developing Mesothelioma NCT01590472 | Wake Forest University | — |
| Completed | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma NCT01362790 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma NCT01356251 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies NCT01401907 | Massachusetts General Hospital | N/A |
| Terminated | Pulmonary Interstitial Lymphography in Early Stage Lung Cancer NCT01188486 | Stanford University | N/A |
| Completed | Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT) NCT01134146 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Combination Gene Transfer and Chemotherapy NCT01119664 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Recruiting | Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies NCT02073500 | Oslo University Hospital | — |
| Unknown | Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma NCT00996385 | Columbia University | Phase 2 |
| Completed | Isolated Thoracic Perfusion (ITP-F) for MPM NCT02467426 | Medias Klinikum for Surgical Oncology | — |
| Completed | Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901) NCT01204203 | University of Alabama at Birmingham | Phase 2 |
| Withdrawn | CryoSpray Ablation(tm)Thoracic Patient Registry NCT00785239 | CSA Medical, Inc. | — |
| Terminated | Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma NCT00895648 | University Health Network, Toronto | Phase 2 |
| Completed | B-Receptor Signaling in Cardiomyopathy NCT01135849 | Daniel Bernstein | — |
| Active Not Recruiting | Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura NCT00715611 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Sorafenib in Previously Treated Malignant Mesothelioma NCT00794859 | King's College London | Phase 2 |
| Terminated | CryoSpray Ablation(tm)in Malignant Airway Disease to Determine Safety, and Tissue Effect in the Lung (ICE the NCT00748085 | CSA Medical, Inc. | N/A |
| Unknown | Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma NCT01281800 | Institute of Oncology Ljubljana | Phase 2 |
| Completed | Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors NCT00703638 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Withdrawn | A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Ad NCT00668499 | University of Southern California | Phase 1 / Phase 2 |
| Unknown | An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma NCT00685204 | Taxolog Inc. | Phase 2 |
| Terminated | N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy NCT00637624 | Rijnstate Hospital | N/A |
| Completed | Mesothelioma Avastin Plus Pemetrexed-cisplatin Study NCT00651456 | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 / Phase 3 |
| Unknown | A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Maligna NCT00551252 | Gruppo Italiano MEsotelioma | Phase 2 |
| Terminated | An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma NCT00597116 | Genzyme, a Sanofi Company | Phase 2 |
| Terminated | SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma NCT01445392 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or NCT00535951 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide NCT00629343 | Columbia University | Phase 1 |
| Terminated | Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothe NCT00604461 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Completed | Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesotheli NCT00407459 | Armando Santoro, MD | Phase 2 |
| Unknown | Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis NCT00454519 | Wuhan University | Phase 2 |
| Completed | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced C NCT00423254 | Mannkind Corporation | Phase 1 |
| Completed | Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen NCT00316225 | Eli Lilly and Company | Phase 2 |
| Completed | Tomotherapy Treatment for Mesothelioma NCT00469196 | AHS Cancer Control Alberta | Phase 2 |
| Completed | Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma NCT00402766 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Can NCT00325494 | Morphotek | Phase 1 |
| Completed | Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma NCT00101283 | Eastern Cooperative Oncology Group | Phase 2 |
| Completed | Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma NCT00295503 | University of Texas Southwestern Medical Center | Phase 2 |
| Completed | Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesotheliom NCT00128102 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers NCT00188890 | University Health Network, Toronto | — |
| Terminated | Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum NCT00094978 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma NCT00859469 | Columbia University | Phase 2 |
| Completed | Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma NCT00137826 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Serum Biomarkers in Diagnosis of Mesothelioma NCT02029105 | Eskisehir Osmangazi University | — |
| Completed | An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma NCT00787410 | AstraZeneca | Phase 2 |
| Completed | Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesot NCT00061477 | Eli Lilly and Company | Phase 2 |
| Completed | A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of M NCT00190762 | Eli Lilly and Company | Phase 3 |
| Completed | Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy NCT00004547 | National Cancer Institute (NCI) | Phase 2 |
| Approved For Marketing | ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma. NCT00040625 | Eli Lilly and Company | — |